You need to login...
If you are not registered...
| Subscribe to Krixos Health: | |
|
or call us on: +43 (0)1 27 63 015 or email: subscribe@krixos.com |
|
Most viewed
- 1. Results from Phase 1/2 Study of Kelun-Biotech's TROP2 ADC Sacituzumab Tirumotecan (sac-TMT) in Patients with Unresectable Locally Advanced or Metastatic Solid Tumors Refractory to Standard Therapies, Published in Journal of Hematology & Oncology
- 2. Prognostic analysis and association of the systemic immune-inflammatory index with immune checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer
- 3. Hyperprogression disease induced by Sintilimab combined with Oxaliplatin and S-1 after surgery: a case report and literature review
- 4. BioNTech buys mRNA, courtroom rival CureVac in all-stock deal
- 5. Exploring a new direction in targeted cancer therapy through hyperbaric oxygen therapy combined with biomedical engineering techniques
- 6. Proton beam therapy for a patient with prostatic rhabdomyosarcoma: a case report and review of the literature
- 7. Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royalties
- 8. Management of multiple primary prostate malignant tumors: case report of synchronous prostatic adenocarcinoma and lymphoma
- 9. The glucocorticoid receptor is a double-edged sword in prostate cancer
- 10. A study led by CIC bioGUNE delves into the complexity of the most aggressive form of prostate cancer
Last updated at 13:41 GMT
Hot News Makers
Health/Pharma Companies
-
224540.05
-
18762.49
-
18760.61
-
18616.38
-
10481.60
-
8473.66
-
7706.56
-
7469.56
-
5849.81
-
4784.96
Drugs, Treatments, Trials
-
59910.91
-
14393.32
-
9863.04
-
7777.09
-
6032.83
-
2321.99
-
1716.24
-
927.95
-
916.91
-
824.84
Last updated at 13:10 GMT
